S
Sophiris Bio
Prostate Gland, Clinical Trials, Clinical Studies, Urinary Tract Symptoms, Sexual Side Effects, Painful Urination, BPH Symptom Relief, Enlarged Prostate, BPH
About Sophiris Bio
Sophiris Bio Inc. is a biopharmaceutical company focused on developing innovative treatments for urological diseases, particularly benign prostatic hyperplasia (BPH) and localized prostate cancer. The company operates in the healthcare and biotechnology market, targeting patients suffering from these specific conditions. Sophiris' primary product candidate, topsalysin, is designed to provide a minimally invasive treatment option for BPH and localized prostate cancer, aiming to improve patient outcomes and quality of life.
Sophiris' business model revolves around the research, development, and potential commercialization of its proprietary drug candidates. The company generates revenue through partnerships, licensing agreements, and potential future sales of its products. However, as of the latest updates, Sophiris has faced significant financial challenges, including outstanding liabilities exceeding its assets and an inability to secure additional funding or partnerships to continue its operations.
Due to these financial difficulties, the company's board of directors has approved an immediate shutdown of operations. This decision was driven by the inability to find a partner or raise capital to support the continued development of topsalysin. As a result, Sophiris will begin the process of shutting down, with no funds available for distribution to shareholders.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Founded
- 2002
- Headquarters
- San Diego, United States
- Listing
- IPO 2013
- Employees
- 5
- Open positions
- None listed
- Dealroom signal
- 25.0/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Oncology, Clinical, Non-Invasive medical devices and treatments, Tech for Biotech and Pharma, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Client focus
- b2c
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| POST IPO DEBT✓Debt | Sep 2017 | $10M | — | Silicon Valley Bank | — |
| POST IPO EQUITY✓Other financing | May 2014 | $2M | — | Warburg Pincus | — |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
| Year | Revenue | Growth |
|---|---|---|
| 2026 | $5M | 0% |
| 2025 | $5M | 0% |
| 2024 | $5M | 0% |
| 2023 | $5M | 0% |
| 2022 | $5M | 0% |
| 2021 | $5M | 0% |
| 2020 | $5M | — |
Growth signals
Latest recorded traffic for Sophiris Bio is 1.3K monthly website visits, down 18.8% over the last three months. Sophiris Bio's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series B and later2 investors entered at this stage
Other known investors1 additional known investor
Sofinnova Investments
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Sophiris Bio on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Sophiris Bio’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.